Document is current

Article History

Received: 8 March 2023

Revised: 13 July 2023

Accepted: 20 July 2023

First Online: 2 August 2023

Declarations

:

: EGY has received research funds (grants paid to the institution) from: Abbvie, Amgen, Asana BioSciences, AstraZeneca, Akari, AnaptysBio, Boehringer-Ingelheim, Eli Lilly, Galderma, Ichnos Sciences, Innovaderm Research, Janssen, Kiniksa, Kyowa Kirin, Leo. Pharma, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sienna Biopharma, UCB, Union Therapeutics; and has been a consultant for Abbvie, Almirall, Amgen, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, Aslan Pharmaceuticals, Bristol Myers. Squibb, Boehringer-Ingelheim, Cara Therapeutics, Castle Biosciences, DBV Technologies, DS Biopharma, Eli Lilly, Evommune, Galderma, Genzyme Corporation, GSK, Ichnos Sciences, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Novan, Novartis, RAPT Therapeutics, Sanofi, Sato Pharmaceutical, Siolta, Union Therapeutics, and Ventyx. BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Incyte, Rapt Therapeutics, and Pfizer. He is also a consultant for Arcutis Biotherapeutics, Castle Biosciences, Fresenius Kabi, Pfizer, and Sanofi. The rest of the authors declare no relevant conflicts of interest.